Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHS-006 + toripalimab
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CHS-006 + toripalimab is a combination of two monoclonal antibodies: **CHS-006**, a TIGIT-targeted antibody, and **toripalimab**, a PD-1-targeted antibody. Both are investigational immunotherapies given intravenously, currently assessed for the treatment of advanced solid tumors. CHS-006 blocks TIGIT, an inhibitory receptor, enhancing T-cell and NK-cell mediated anti-tumor responses. Toripalimab inhibits PD-1, a checkpoint receptor, restoring and augmenting T-cell anti-tumor activity. The combination is designed to provide synergistic immune activation against tumor cells, with the aim of improved efficacy over single-agent checkpoint inhibition. Phase 1 trials are ongoing to assess safety, pharmacokinetics, and early efficacy for multiple advanced solid tumor types[6][7][8][9].
- Other names
- CHS-006 + toripalimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on CHS-006 + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHS-006 + toripalimab.